OPSENS SIGNS DEFINITIVE AGREEMENT FOR ITS ACQUISITION BY HAEMONETICS

All amounts in this press release are in Canadian dollars.

QUÉBEC CITY, QC, Oct. 10, 2023 /CNW/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX:OPS.TO) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") with Haemonetics Corporation ("Haemonetics") (NYSE: HAE), a global healthcare company, and 9500-7704 Québec Inc., a wholly-owned subsidiary of Haemonetics ("AcquireCo" and, collectively with Haemonetics, the "Purchaser Parties"), whereby Haemonetics will indirectly acquire (the "Transaction") all of the issued and outstanding common shares in the capital of OpSens (the "Shares").